ARCHIVED - Formative Evaluation of the Canadian HIV Vaccine Initiative
Appendix H: Results of Grant Awards
Catalyst Grant
Memorial University of Newfoundland ($100,000, 1 year) – Heteroclitic Peptides to Increase Human Immunodeficiency Virus-specific CD8+ T cell Interleukin-2 Production
Institut de recherches cliniques de Montréal ($100,000, 1 year) – Dissecting the mechanisms of protection by attenuated Nef-deleted HIV vaccine
Université Laval ($100,000, 1 year) – Promoting innate immunity to HIV infection by vaccine delivery of third generation RNA analogs
McMaster University ($100,000, 1 year) – Functional correlate of mucosal antibody response to HIV infection in blood
Université Laval ($100,000, 1 year) – A new human cell experimental system for evaluating prototype HIV-1 vaccines
Mario Ostrowski, University of Toronto ($99,252) – Discovery of new B cell immunogens for HIV vaccines
University of Saskatchewan ($89,482) – A combined early and late HIV-1 protein-specific exosome-targeted T cell vaccine capable of stimulating HIV-1 specific CD8+ CTL responses in absence of CD4+ T cells and counteracting immune suppression
University of Manitoba ($100,000) – Attacking HIV protease cleavage sites with immunization - Explore the rapid mutation rate of HIV-1
Operating Grants
The Research Institute of the McGill University Health Centre ($440,604, 3 years) – The functional profile of NK cells in HIV exposed uninfected subjects: Association with carriage of NK receptor-HLA ligand genotypes.
Jewish General Hospital, Montreal ($327,993, 3 years) – The potential of APOBEC3G in the development of a novel anti-HIV-1 therapeutic
University of Manitoba ($663,050, 5 years) – The effect of the CD4 pathogenicity island on HIV susceptibility and disease progression
Jewish General Hospital, Montreal ($721,347, 5 years) – Studying the antiviral activity of bone marrow stromal cell antigen 2 and the countering mechanism from HIV-1 Vpu
Université Laval ($391,824, 3 years) – A comparative immunogenicity study of HIV-1 Pr160Gag-Pol virus-like particles bearing gp120, CD40L and/or TLR5 agonist flagellin
Emerging Team Grants
(Approved to submit a full application – awards expected March 2010)
niversity of Manitoba ($10,000) – Research on the social and cultural aspects of implementing HIV vaccine programs among MSM and FSWs in Asia and Africa
University of Toronto ($10,000) – HIV Vaccine Design based on Novel Strategies to induce Protective Mucosal Cellular and Humoral Immunity
University of Toronto ($10,000) – Enhancing Care and Prevention in HIV Vaccine Trials: An International, Interdisciplinary Collaboration
Simon Fraser ($10,000) – Prophylactic HIV Vaccines for Social Networks of Injection Drug Users
University of British Columbia ($10,000) – At the Crossroads of Vertical and Horizontal HIV Transmission: The HIV-Exposed Uninfected Infant as a Window into Successful HIV Vaccine Design
Health Canada Community Engagement Grants
UNAIDS ($85,000)
WHO African AIDS Vaccine Programme ($95,000)
Community Initiative Grants
Canadian AIDS Society ($268,300.75)
International Coalition on AIDS & Development ($290,000)
Page details
- Date modified: